JP2009535039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535039A5 JP2009535039A5 JP2009507985A JP2009507985A JP2009535039A5 JP 2009535039 A5 JP2009535039 A5 JP 2009535039A5 JP 2009507985 A JP2009507985 A JP 2009507985A JP 2009507985 A JP2009507985 A JP 2009507985A JP 2009535039 A5 JP2009535039 A5 JP 2009535039A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- nucleotide
- cell
- virus
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701460 JC polyomavirus Species 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 23
- 230000000295 complement effect Effects 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000000692 anti-sense effect Effects 0.000 claims description 9
- 108091081021 Sense strand Proteins 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 3
- 208000035657 Abasia Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 230000029812 viral genome replication Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- ONKSSDKXDIVIHK-UHFFFAOYSA-N n,n-didecyldodecanamide Chemical group CCCCCCCCCCCC(=O)N(CCCCCCCCCC)CCCCCCCCCC ONKSSDKXDIVIHK-UHFFFAOYSA-N 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- -1 cationic lipid Chemical class 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79576506P | 2006-04-28 | 2006-04-28 | |
| US60/795,765 | 2006-04-28 | ||
| PCT/US2007/067628 WO2007127919A2 (en) | 2006-04-28 | 2007-04-27 | Compositions and methods for inhibiting expression of a gene from the jc virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011066818A Division JP5398769B2 (ja) | 2006-04-28 | 2011-03-24 | Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009535039A JP2009535039A (ja) | 2009-10-01 |
| JP2009535039A5 true JP2009535039A5 (enExample) | 2011-05-12 |
| JP4812874B2 JP4812874B2 (ja) | 2011-11-09 |
Family
ID=38656415
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507985A Expired - Fee Related JP4812874B2 (ja) | 2006-04-28 | 2007-04-27 | Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法 |
| JP2011066818A Expired - Fee Related JP5398769B2 (ja) | 2006-04-28 | 2011-03-24 | Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法 |
| JP2013218877A Withdrawn JP2014036665A (ja) | 2006-04-28 | 2013-10-22 | Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011066818A Expired - Fee Related JP5398769B2 (ja) | 2006-04-28 | 2011-03-24 | Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法 |
| JP2013218877A Withdrawn JP2014036665A (ja) | 2006-04-28 | 2013-10-22 | Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US7691824B2 (enExample) |
| EP (1) | EP2013222B1 (enExample) |
| JP (3) | JP4812874B2 (enExample) |
| WO (1) | WO2007127919A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892795B2 (en) | 2005-08-02 | 2011-02-22 | Focus Diagnostics, Inc. | Methods and compositions for detecting BK virus |
| EP2013222B1 (en) * | 2006-04-28 | 2013-02-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the jc virus |
| US20110118340A1 (en) * | 2008-02-08 | 2011-05-19 | Muthiah Manoharan | Delivery of rnai constructs to oligodendrocytes |
| WO2010141511A2 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| WO2012143427A1 (en) * | 2011-04-19 | 2012-10-26 | Santaris Pharma A/S | Anti polyomavirus compounds |
| US20140255915A1 (en) * | 2011-07-29 | 2014-09-11 | Biogen Idec Ma Inc. | Assay for detection of jc virus dna |
| EP3047023B1 (en) * | 2013-09-19 | 2019-09-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for inhibiting jc virus (jcv) |
| MA40880A (fr) * | 2014-10-30 | 2017-09-05 | Temple Univ Of The Commonwealth | Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus |
| WO2017035278A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
| RU2018124657A (ru) * | 2015-12-09 | 2020-01-09 | Эксижн Биотерапевтикс, Инк. | Способы редактирования генов и композиции для устранения риска активации вируса jc и пмл (прогрессирующая мультифокальная лейкоэнцефалопатия) во время иммуносупрессивной терапии |
| CA3092817A1 (en) * | 2018-03-02 | 2019-09-06 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Inhibition of polyomavirus replication |
| IL316802A (en) * | 2022-05-06 | 2025-01-01 | Academisch Ziekenhuis Leiden | Oligonucleotide |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
| WO1987000201A1 (en) | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| EP0633318A1 (en) | 1987-09-11 | 1995-01-11 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| DE3851153T2 (de) | 1987-12-11 | 1995-01-05 | Hughes Howard Med Inst | Genetische modifizierung von endothelialen zellen. |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5103556A (en) | 1988-05-05 | 1992-04-14 | Circon Corporation | Method of manufacturing an electrohydraulic probe |
| GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
| JP3418982B2 (ja) | 1990-10-31 | 2003-06-23 | ソマティクス セラピー コーポレイション | 内皮細胞の遺伝的変性 |
| JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
| KR100334858B1 (ko) | 1993-02-19 | 2006-01-27 | 니뽄 신야쿠 가부시키가이샤 | 핵산공중합체를함유하는의약조성물 |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5540935A (en) | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
| US6054299A (en) | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| DE69629702T2 (de) | 1995-08-01 | 2004-06-17 | Isis Pharmaceuticals, Inc., Carlsbad | Liposomale oligonukleotidzusammensetzungen |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| EP1068311B2 (en) | 1998-04-08 | 2020-12-09 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
| AR020078A1 (es) | 1998-05-26 | 2002-04-10 | Syngenta Participations Ag | Metodo para alterar la expresion de un gen objetivo en una celula de planta |
| KR20010099682A (ko) | 1998-10-09 | 2001-11-09 | 추후보충 | 단일가닥 ｄｎａ의 효소 합성 |
| AU6298899A (en) | 1998-10-09 | 2000-05-01 | Ingene, Inc. | Production of ssdna (in vivo) |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6359700B1 (en) | 1999-04-26 | 2002-03-19 | Hewlett-Packard Company | Method and apparatus for preventing print overruns by rasterizing complex page strips using an auxiliary processor |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7923547B2 (en) * | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| EP3450559A1 (en) | 2003-03-07 | 2019-03-06 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
| EP1608735A4 (en) | 2003-04-03 | 2008-11-05 | Alnylam Pharmaceuticals | RNAI CONJUGATES |
| ES2702942T3 (es) * | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| EP1753292A4 (en) | 2004-05-12 | 2007-09-26 | Kamel Khalili | COMPOSITIONS AND METHODS FOR INHIBITING ARNIC GENES OF PRIMATE POLYOMA VIRUS |
| JP4672654B2 (ja) | 2004-05-24 | 2011-04-20 | 独立行政法人科学技術振興機構 | ＪＣウイルスのＶＰ−１に対するｓｉＲＮＡ、及びそれを含有してなる医薬組成物 |
| US7427605B2 (en) | 2005-03-31 | 2008-09-23 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| WO2007115168A2 (en) | 2006-03-31 | 2007-10-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 gene |
| EP2013222B1 (en) * | 2006-04-28 | 2013-02-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the jc virus |
| US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
-
2007
- 2007-04-27 EP EP20070761452 patent/EP2013222B1/en not_active Not-in-force
- 2007-04-27 US US11/741,205 patent/US7691824B2/en not_active Expired - Fee Related
- 2007-04-27 JP JP2009507985A patent/JP4812874B2/ja not_active Expired - Fee Related
- 2007-04-27 WO PCT/US2007/067628 patent/WO2007127919A2/en not_active Ceased
-
2010
- 2010-03-09 US US12/720,465 patent/US8058257B2/en not_active Expired - Fee Related
-
2011
- 2011-03-24 JP JP2011066818A patent/JP5398769B2/ja not_active Expired - Fee Related
- 2011-10-04 US US13/252,414 patent/US8410261B2/en not_active Expired - Fee Related
-
2013
- 2013-02-27 US US13/779,116 patent/US9012624B2/en not_active Expired - Fee Related
- 2013-10-22 JP JP2013218877A patent/JP2014036665A/ja not_active Withdrawn
-
2015
- 2015-03-12 US US14/645,922 patent/US20150240237A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535039A5 (enExample) | ||
| US20240238326A1 (en) | Compositions and methods for modulation of smn2 splicing in a subject | |
| TWI811238B (zh) | 用於抑制脂蛋白元C-III(APOC3)表現之RNAi試劑及組合物 | |
| TWI836693B (zh) | 抑制ｌｐａ之基因表現之組合物及方法 | |
| JP5066095B2 (ja) | 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節 | |
| EP2516647B1 (en) | Molecule for treating an inflammatory disorder | |
| CA2754043A1 (en) | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes | |
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| US20230074280A1 (en) | Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts | |
| CN111918968B (zh) | Micro-RNA 22的抑制剂 | |
| US20250228883A1 (en) | Process to Inhibit or Eliminate Eosinophilic Diseases of the Airway and Related Conditions | |
| KR20240053627A (ko) | 안지오포이에틴-유사 3(angptl3) 단백질의 발현을 억제하기 위한 조성물 및 방법 | |
| KR20220158011A (ko) | PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법 | |
| EP2389390A2 (en) | Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil | |
| US20210322526A1 (en) | Enzymatic replacement therapy and antisense therapy for pompe disease | |
| KR20010042848A (ko) | 인슐린유사 성장인자 ⅱ의 안티센스 올리고뉴클레오타이드서열 및 이를 이용한 세포성장 조절방법 | |
| KR20240040112A (ko) | 방법 | |
| CN103221540B (zh) | 病毒基因组中的高度保守区序列作为设计治疗性sliRNA模板的应用 | |
| WO2020148400A1 (en) | Antisense oligonucleotides for use in the treatment of crpc | |
| Caroleo et al. | Overview of microrna-based therapeutics | |
| CN114829601A (zh) | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| JP2024541719A (ja) | シクロフィリンｄ関連疾患の処置方法 | |
| US20220127610A1 (en) | Oligonucleotides for use in the treatment of dystrophic epidermolysis bullosa | |
| JP2024057599A (ja) | マイクロｒｎａ２２の阻害剤 | |
| TW202444904A (zh) | 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法 |